Blood Cancer Journal · 2023 · 40 citations · 19 references
MedicineHematologyOncologyChemotherapyHematologic OncologyMedical OncologyHematologic MalignanciesHematologic Malignancy TherapyLymphoid NeoplasmsMinimal Residual DiseaseAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentB-cell Acute Lymphoblastic LeukemiaB-cell LeukemiaB-cell Malignancy TherapyBlinatumomab TherapyExpanded Access UseRefractory Acute Lymphoblastic Leukemia
This retrospective observational study (NEUF) included adult patients with B-cell acute lymphoblastic leukemia (B-cell ALL) who had received blinatumomab for the treatment of minimal residual disease-positive (MRD+) or relapsed/refractory (R/R) B-cell ALL via an expanded access program (EAP). Patients were eligible if blinatumomab was initiated via the EAP between January 2014 and June 2017. Patients were followed from blinatumomab initiation until death, entry into a clinical trial, the end of follow-up, or the end of the study period (December 31, 2017), whichever occurred first. Of the 249 adult patients included, 109 were MRD+ (83 Philadelphia chromosome-negative [Ph-] and 26 Philadelphia chromosome-positive [Ph+]) and 140 had a diagnosis of R/R B-cell ALL (106 Ph- and 34 Ph+). In the MRD+ group, within the first cycle of blinatumomab treatment, 93% (n = 49/53) of Ph- and 64% (n = 7/11) of Ph+ patients with evaluable MRD achieved an MRD response (MRD <0.01%). Median overall survival (OS) was not reached over a median follow-up time of 18.5 months (Ph-, 18.8 [range: 5.1-34.8] months; Ph+, 16.5 [range: 1.8-31.6] months). In the R/R group, within two cycles of blinatumomab, 51% of Ph- and 41% of Ph+ patients achieved complete hematologic remission (CR/CRh/CRi), and 83% of Ph- and 67% of Ph+ MRD-evaluable patients in CR/CRh/CRi achieved an MRD response. Median (95% confidence interval) OS was 12.2 (7.3-24.2) months in the R/R Ph- subgroup and 16.3 (5.3-not estimated) months in the R/R Ph+ subgroup. This large, real-world data set of adults with B-cell ALL treated with blinatumomab confirms efficacy outcomes from published studies.
19
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text
Medicine, Hematology, Oncology +16
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier et al. · Science · 2008 · 1.1K citations
Life Sciences, Immunology, Oncology +17
Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2018 · 845 citations · Full text
Medicine, Hematology, Oncology +13
Anthony V. Moorman, Christine J. Harrison, Georgina Buck et al. · Blood · 2006 · 748 citations · Full text
Life Sciences, Hematology, Oncology +14